Biomarkers of PARP inhibitor sensitivity
- 8 February 2011
- journal article
- editorial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 127 (1) , 283-286
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 2010
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 2010
- First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.Journal of Clinical Oncology, 2010
- Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.Journal of Clinical Oncology, 2010
- A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.Journal of Clinical Oncology, 2010
- Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trialJournal of Clinical Oncology, 2009
- Basic fibroblast growth factor (FGF‐2): The high molecular weight forms come of ageJournal of Cellular Biochemistry, 2006
- Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase InhibitionCancer Research, 2006
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian TumorsJNCI: Journal of the National Cancer Institute, 2000